|
1
|
Torre LA, Siegel RL, Ward EM and Jemal A:
Global cancer incidence and mortality rates and trends-an update.
Cancer Epidemiol Biomarkers Prev. 25:16–27. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Burt R: Inheritance of colorectal cancer.
Drug Discov Today Dis Mech. 4:293–300. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hendon SE and DiPalma JA: U.S. practices
for colon cancer screening. Keio J Med. 54:179–183. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lengauer C, Kinzler KW and Vogelstein B:
Genetic instabilities in human cancers. Nature. 396:643–649. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Markowitz SD and Bertagnolli MM: Molecular
origins of cancer: Molecular basis of colorectal cancer. N Engl J
Med. 361:2449–2460. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tsang AH, Cheng KH, Wong AS, Ng SS, Ma BB,
Chan CM, Tsui NB, Chan LW, Yung BY and Wong SC: Current and future
molecular diagnostics in colorectal cancer and colorectal adenoma.
World J Gastroenterol. 20:3847–3857. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Grady WM and Pritchard CC: Molecular
alterations and biomarkers in colorectal cancer. Toxicol Pathol.
42:124–139. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fransén K, Klintenäs M, Österström A,
Dimberg J, Monstein HJ and Söderkvist P: Mutation analysis of the
BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas.
Carcinogenesis. 25:527–533. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pino MS and Chung DC: The chromosomal
instability pathway in colon cancer. Gastroenterology.
138:2059–2072. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lynch HT and de la Chapelle A: Hereditary
colorectal cancer. N Engl J Med. 348:919–932. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fearon ER and Vogelstein B: A genetic
model for colorectal tumorigenesis. Cell. 61:759–767. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Grady WM: Epigenetic events in the
colorectum and in colon cancer. Biochem Soc Trans. 33:684–688.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kinzler KW and Vogelstein B: Lessons from
hereditary colorectal cancer. Cell. 87:159–170. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tejpar S and Van Cutsem E: Molecular and
genetic defects in colorectal tumorigenesis. Best Pract Res Clin
Gastroenterol. 16:171–185. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
O'Connell JB, Maggard MA and Ko CY: Colon
cancer survival rates with the new American Joint Committee on
Cancer sixth edition staging. J Natl Cancer Inst. 96:1420–1425.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Reimers MS, Zeestraten EC, Kuppen PJ,
Liefers GJ and van de Velde CJ: Biomarkers in precision therapy in
colorectal cancer. Gastroenterol Rep (Oxf). 1:166–183. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nachman MW and Crowell SL: Estimate of the
mutation rate per nucleotide in humans. Genetics. 156:297–304.
2000.PubMed/NCBI
|
|
20
|
Roach JC, Glusman G, Smit AF, Huff CD,
Hubley R, Shannon PT, Rowen L, Pant KP, Goodman N, Bamshad M, et
al: Analysis of genetic inheritance in a family quartet by
whole-genome sequencing. Science. 328:636–639. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Loeb LA, Loeb KR and Anderson JP: Multiple
mutations and cancer. Proc Natl Acad Sci USA. 100:776–781. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Markowitz S, Wang J, Myeroff L, Parsons R,
Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, Vogelstein
B, et al: Inactivation of the type II TGF-beta receptor in colon
cancer cells with microsatellite instability. Science.
268:1336–1338. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Samuels Y, Wang Z, Bardelli A, Silliman N,
Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riqqins GJ, et al:
High frequency of mutations of the PIK3CA gene in human cancers.
Science. 304:5542004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Baker SJ, Fearon ER, Nigro JM, Hamilton
SR, Preisinger AC, Jessup JM, vanTuinen P, Ledbetter DH, Barker DF,
Nakamura Y, et al: Chromosome 17 deletions and p53 gene mutations
in colorectal carcinomas. Science. 244:217–221. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Thiagalingam S, Lengauer C, Leach FS,
Schutte M, Hahn SA, Overhauser J, Willson JK, Markowitz S, Hamilton
SR, Kern SE, et al: Evaluation of candidate tumour suppressor genes
on chromosome 18 in colorectal cancers. Nat Genet. 13:343–346.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Diep CB, Kleivi K, Ribeiro FR, Teixeira
MR, Lindgjærde OC and Lothe RA: The order of genetic events
associated with colorectal cancer progression inferred from
meta-analysis of copy number changes. Genes Chromosomes Cancer.
45:31–41. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jasmine F, Rahaman R, Dodsworth C, Roy S,
Paul R, Raza M, Paul-Brutus R, Kamal M, Ahsan H and Kibriya MG: A
genome-wide study of cytogenetic changes in colorectal cancer using
SNP microarrays: Opportunities for future personalized treatment.
PLoS One. 7:e319682012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Baudis M: Genomic imbalances in 5918
malignant epithelial tumors: An explorative meta-analysis of
chromosomal CGH data. BMC Cancer. 7:2262007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jones AM, Douglas EJ, Halford SE, Fiegler
H, Gorman PA, Roylance RR, Carter NP and Tomlinson IP: Array-CGH
analysis of microsatellite-stable, near-diploid bowel cancers and
comparison with other types of colorectal carcinoma. Oncogene.
24:118–129. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zarzour P, Boelen L, Luciani F, Beck D,
Sakthianandeswaren A, Mouradov D, Sieber OM, Hawkins NJ, Hesson LB,
Ward RL and Wong JW: Single nucleotide polymorphism array profiling
identifies distinct chromosomal aberration patterns across
colorectal adenomas and carcinomas. Genes Chromosomes Cancer.
54:303–314. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cancer Genome Atlas Network: Comprehensive
molecular characterization of human colon and rectal cancer.
Nature. 487:330–337. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Foulds L: The natural history of cancer. J
Chronic Dis. 8:2–37. 1958. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nowell PC: The clonal evolution of tumor
cell populations. Science. 194:23–28. 1976. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Nguyen HT, Geens M and Spits C: Genetic
and epigenetic instability in human pluripotent stem cells. Hum
Reprod Update. 19:187–205. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lund RJ, Närvä E and Lahesmaa R: Genetic
and epigenetic stability of human pluripotent stem cells. Nat Rev
Genet. 13:732–744. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
International Stem Cell Initiative, . Amps
K, Andrews PW, Anyfantis G, Armstrong L, Avery S, Baharvand H,
Baker J, Barker D, Munoz MB, et al: Screening ethnically diverse
human embryonic stem cells identifies a chromosome 20 minimal
amplicon conferring growth advantage. Nat Biotechnol. 29:1132–1144.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Nguyen HT, Geens M, Mertzanidou A, Jacobs
K, Heirman C, Breckpot K and Spits C: Gain of 20q11.21 in human
embryonic stem cells improves cell survival by increased expression
of Bcl-xL. Mol Hum Reprod. 20:168–177. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Avery S, Hirst AJ, Baker D, Lim CY,
Alagaratnam S, Skotheim RI, Lothe RA, Pera MF, Colman A, Robson P,
et al: BCL-XL Mediates the strong selective advantage of a 20q11.21
amplification commonly found in human embryonic stem cell cultures.
Stem Cell Reports. 1:379–386. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Beroukhim R, Mermel CH, Porter D, Wei G,
Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J,
Urashima M, et al: The landscape of somatic copy-number alteration
across human cancers. Nature. 463:899–905. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Vogelstein B, Fearon ER, Hamilton SR, Kern
SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM and Bos
JL: Genetic alterations during colorectal-tumor development. N Engl
J Med. 319:525–532. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ogino S, Nosho K, Irahara N, Shima K, Baba
Y, Kirkner GJ, Meyerhardt JA and Fuchs CS: Prognostic significance
and molecular associations of 18q loss of heterozygosity: A cohort
study of microsatellite stable colorectal cancers. J Clin Oncol.
27:4591–4598. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sheffer M, Bacolod MD, Zuk O, Giardina SF,
Pincas H, Barany F, Paty PB, Gerald WL, Notterman DA and Domany E:
Association of survival and disease progression with chromosomal
instability: A genomic exploration of colorectal cancer. Proc Natl
Acad Sci USA. 106:7131–7136. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Jen J, Kim H, Piantadosi S, Liu ZF, Levitt
RC, Sistonen P, Kinzler KW, Vogelstein B and Hamilton SR: Allelic
loss of chromosome 18q and prognosis in colorectal cancer. N Engl J
Med. 331:213–221. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zauber P, Sabbath-solitare M, Marotta SP
and Bishop T: Loss of heterozygosity for chromosome 18q and
microsatellite instability are highly consistent across the region
of the DCC and SMAD4 genes in colorectal carcinomas and adenomas. J
Appl Res. 8:14–23. 2008.
|
|
45
|
Fearon ER, Cho KR, Nigro JM, Kern SE,
Simons JW, Ruppert JM, Hamilton SR, Preisinger AC, Thomas G,
Kinzler KW, et al: Identification of a chromosome 18q gene that is
altered in colorectal cancers. Science. 247:49–56. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Mehlen P and Fearon ER: Role of the
dependence receptor DCC in colorectal cancer pathogenesis. J Clin
Oncol. 22:3420–3428. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Alazzouzi H, Alhopuro P, Salovaara R,
Sammalkorpi H, Järvinen H, Mecklin JP, Hemminki A, Schwartz S Jr,
Aaltonen LA and Arango D: SMAD4 as a prognostic marker in
colorectal cancer. Clin Cancer Res. 11:2606–2611. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Grady WM: Genomic instability and colon
cancer. Cancer Metastasis Rev. 23:11–27. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Shi Y, Hata A, Lo RS, Massagué J and
Pavletich NP: A structural basis for mutational inactivation of the
tumour suppressor Smad4. Nature. 388:87–93. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Hahn SA, Schutte M, Hoque AT, Moskaluk CA,
da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hurban
RH and Kern SE: DPC4, a candidate tumor suppressor gene at human
chromosome 18q21.1. Science. 271:350–353. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Takagi Y, Kohmura H, Futamura M, Kida H,
Tanemura H, Shimokawa K and Saji S: Somatic alterations of the DPC4
gene in human colorectal cancers in vivo. Gastroenterology.
111:1369–1372. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Takagi Y, Koumura H, Futamura M, Aoki S,
Ymaguchi K, Kida H, Tanemura H, Shimokawa K and Saji S: Somatic
alterations of the SMAD-2 gene in human colorectal cancers. Br J
Cancer. 78:1152–1155. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Fleming NI, Jorissen RN, Mouradov D,
Christie M, Sakthianandeswaren A, Palmieri M, Day F, Li S, Tsui C,
Lipton L, et al: SMAD2, SMAD3 and SMAD4 mutations in colorectal
cancer. Cancer Res. 73:725–735. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Takebayashi S, Ogawa T, Jung KY, Muallem
A, Mineta H, Fisher SG, Grenman R and Carey TE: Identification of
new minimally lost regions on 18q in head and neck squamous cell
carcinoma. Cancer Res. 60:3397–3403. 2000.PubMed/NCBI
|
|
55
|
Powell SM, Zilz N, Beazer-Barclay Y, Bryan
TM, Hamilton SR, Thibodeau SN, Vogelstein B and Kinzler KW: APC
mutations occur early during colorectal tumorigenesis. Nature.
359:235–237. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
MacDonald BT, Tamai K and He X:
Wnt/beta-catenin signaling: Components, mechanisms, and diseases.
Dev Cell. 17:9–26. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Stanczak A, Stec R, Bodnar L, Olszewski W,
Cichowicz M, Kozlowski W, Szcylik C, Pietrucha T, Wieczorek M and
Lamparska-Pzybysz M: Prognostic significance of Wnt-1, β-catenin
and E-cadherin expression in advanced colorectal carcinoma. Pathol
Oncol Res. 17:955–963. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Morin PJ, Sparks AB, Korinek V, Barker N,
Clevers H, Vogelstein B and Kinzler KW: Activation of β-catenin-Tcf
signaling in colon cancer by mutations in beta-catenin or APC.
Science. 275:1787–1790. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Liu W, Dong X, Mai M, Seelan RS, Taniguchi
K, Krishnadath KK, Halling KC, Cunningham JM, Boardman LA, Qian C,
et al: Mutations in AXIN2 cause colorectal cancer with defective
mismatch repair. Nat Genet. 26:146–147. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Coppedè F, Lopomo A, Spisni R and Migliore
L: Genetic and epigenetic biomarkers for diagnosis, prognosis and
treatment of colorectal cancer. World J Gastroenterol. 20:943–956.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Kapitanović S, Cacev T, Radosević S,
Spaventi S, Spaventi R and Pavelić K: APC gene loss of
heterozygosity, mutations, E1317Q, and I1307K germ-line variants in
sporadic colon cancer in Croatia. Exp Mol Pathol. 77:193–200. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Esteller M: Epigenetic lesions causing
genetic lesions in human cancer: Promoter hypermethylation of DNA
repair genes. Eur J Cancer. 36:2294–2300. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Levine AJ: P53, the cellular gatekeeper
for growth and division. Cell. 88:323–331. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
el-Deiry WS: Regulation of p53 downstream
genes. Semin Cancer Biol. 8:345–357. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Li XL, Zhou J, Chen ZR and Chng WJ: P53
mutations in colorectal cancer-molecular pathogenesis and
pharmacological reactivation. World J Gastroenterol. 21:84–93.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Leslie A, Carey FA, Pratt NR and Steele
RJ: The colorectal adenoma-carcinoma sequence. Br J Surg.
89:845–860. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Takayama T, Miyanishi K, Hayashi T, Sato Y
and Niitsu Y: Colorectal cancer: Genetics of development and
metastasis. J Gastroenterol. 41:185–192. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Sigal A and Rotter V: Oncogenic mutations
of the p53 tumor suppressor: The demons of the guardian of the
genome. Cancer Res. 60:6788–6793. 2000.PubMed/NCBI
|
|
69
|
Liu Y and Bodmer WF: Analysis of P53
mutations and their expression in 56 colorectal cancer cell lines.
Proc Natl Acad Sci USA. 103:976–981. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Béroud C and Soussi T: The UMD-p53
database: New mutations and analysis tools. Hum Mutat. 21:176–181.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Vigil D, Cherfils J, Rossman KL and Der
CJ: Ras superfamily GEFs and GAPs: Validated and tractable targets
for cancer therapy? Nat Rev Cancer. 10:842–857. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Schubbert S, Shannon K and Bollag G:
Hyperactive Ras in developmental disorders and cancer. Nat Rev
Cancer. 7:295–308. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Adjei AA: Ras signaling pathway proteins
as therapeutic targets. Curr Pharm Des. 7:1581–1594. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Downward J: Targeting RAS signalling
pathways in cancer therapy. Nat Rev Cancer. 3:11–22. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Forbes SA, Bindal N, Bamford S, Cole C,
Kok CY, Beare D, Jia M, Shepherd R, Leung K, Menzies A, et al:
COSMIC: Mining complete cancer genomes in the catalogue of somatic
mutations in cancer. Nucleic Acids Res. 39:(Database issue).
D945–D950. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Tan C and Du X: KRAS mutation testing in
metastatic colorectal cancer. World J Gastroenterol. 18:5171–5180.
2012.PubMed/NCBI
|
|
77
|
Conlin A, Smith G, Carey FA, Wolf CR and
Steele RJ: The prognostic significance of K-ras, p53, and APC
mutations in colorectal carcinoma. Gut. 54:1283–1286. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Phipps AI, Buchanan DD, Makar KW, Win AK,
Baron JA, Lindor NM, Potter JD and Newcomb PA: KRAS-mutation status
in relation to colorectal cancer survival: The joint impact of
correlated tumour markers. Br J Cancer. 108:1757–1764. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Cejas P, López-Gómez M, Aguayo C, Madero
R, de Castro Carpeño J, Belda-Iniesta C, Barriuso J, García Moreno
V, Larrauri J, López R, et al: KRAS mutations in primary colorectal
cancer tumors and related metastases: A potential role in
prediction of lung metastasis. PLoS One. 4:e81992009. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Kim HS, Heo JS, Lee J, Lee JY, Lee MY, Lim
SH, Lee WY, Kim SH, Park YA, Cho YB, et al: The impact of KRAS
mutations on prognosis in surgically resected colorectal cancer
patients with liver and lung metastases: A retrospective analysis.
BMC Cancer. 16:1202016. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Nash GM, Gimbel M, Shia J, Nathanson DR,
Ndubuisi MI, Zeng ZS, Kemeny N and Paty PB: KRAS mutation
correlates with accelerated metastatic progression in patients with
colorectal liver metastases. Ann Surg Oncol. 17:572–578. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Inoue Y, Saigusa S, Iwata T, Okugawa Y,
Toiyama Y, Tanaka K, Uchida K, Mohri Y and Kusunoki M: The
prognostic value of KRAS mutations in patients with colorectal
cancer. Oncol Rep. 28:1579–1584. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Amado RG, Wolf M, Peeters M, Van Cutsem E,
Siena S, Freeman DJ, Juan T, Sikorski R, Suqqs S, Radinsky R, et
al: Wild-type KRAS is required for panitumumab efficacy in patients
with metastatic colorectal cancer. J Clin Oncol. 26:1626–1634.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Lièvre A, Bachet JB, Boige V, Cayre A, Le
Corre D, Buc E, Ychou M, Bouché O, Landi B, Louvet C, et al: KRAS
mutations as an independent prognostic factor in patients with
advanced colorectal cancer treated with cetuximab. J Clin Oncol.
26:374–379. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Karapetis CS, Khambata-Ford S, Jonker DJ,
O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD,
Robitalle S, et al: K-ras mutations and benefit from cetuximab in
advanced colorectal cancer. N Engl J Med. 359:1757–1765. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Siena S, Sartore-Bianchi A, Di
Nicolantonio F, Balfour J and Bardelli A: Biomarkers predicting
clinical outcome of epidermal growth factor receptor-targeted
therapy in metastatic colorectal cancer. J Natl Cancer Inst.
101:1308–1324. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Bos JL, Fearon ER, Hamilton SR, Verlaan-de
Vries M, van Boom JH, van der Eb AJ and Vogelstein B: Prevalence of
ras gene mutations in human colorectal cancers. Nature.
327:293–297. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Forrester K, Almoguera C, Han K, Grizzle
WE and Perucho M: Detection of high incidence of K-ras oncogenes
during human colon tumorigenesis. Nature. 327:298–303. 1987.
View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Fernández-Medarde A and Santos E: Ras in
cancer and developmental diseases. Genes Cancer. 2:344–358. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Neumann J, Zeindl-Eberhart E, Kirchner T
and Jung A: Frequency and type of KRAS mutations in routine
diagnostic analysis of metastatic colorectal cancer. Pathol Res
Pract. 205:858–862. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Irahara N, Baba Y, Nosho K, Shima K, Yan
L, Dias-Santagata D, Iafrate AJ, Fuchs CS, Haigis KM and Ogino S:
NRAS mutations are rare in colorectal cancer. Diagn Mol Pathol.
19:157–163. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Vaughn CP, ZoBell SD, Furtado LV, Baker CL
and Samowitz WS: Frequency of KRAS, BRAF, and NRAS mutations in
colorectal cancer. Genes Chromosomes Cancer. 50:307–312. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Kosmidou V, Oikonomou E, Vlassi M,
Avlonitis S, Katseli A, Tsipras I, Mourtzoukou D, Kontogeorgos G,
Zografos G and Pintzas A: Tumor heterogeneity revealed by KRAS,
BRAF, and PIK3CA pyrosequencing: KRAS and PIK3CA intratumor
mutation profile differences and their therapeutic implications.
Hum Mutat. 35:329–340. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Abdel-Rahman WM and Peltomäki P: Molecular
basis and diagnostics of hereditary colorectal cancers. Ann Med.
36:379–388. 2014. View Article : Google Scholar
|
|
95
|
Thibodeau SN, Bren G and Schaid D:
Microsatellite instability in cancer of the proximal colon.
Science. 260:816–819. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Boland CR and Goel A: Somatic evolution of
cancer cells. Semin Cancer Biol. 15:436–450. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Boland CR, Thibodeau SN, Hamilton SR,
Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA,
Fodde R, Ranzani GN and Srivastava S: A national cancer institute
workshop on microsatellite instability for cancer detection and
familial predisposition: Development of international criteria for
the determination of microsatellite instability in colorectal
cancer. Cancer Res. 58:5248–5257. 1998.PubMed/NCBI
|
|
98
|
Findeisen P, Kloor M, Merx S, Sutter C,
Woerner SM, Dostmann N, Benner A, Dondog B, Pawlita M, Dippold W,
et al: T25 repeat in the 3′ untranslated region of the CASP2 gene:
A sensitive and specific marker for microsatellite instability in
colorectal cancer. Cancer Res. 65:8072–8078. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Aaltonen LA, Peltomäki P, Leach FS,
Sistonen P, Pylkkänen L, Mecklin JP, Järvinen H, Powell SM, Jen J,
Hamilton SR, et al: Clues to the pathogenesis of familial
colorectal cancer. Science. 260:812–816. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Jiricny J: The multifaceted
mismatch-repair system. Nat Rev Mol Cell Biol. 7:335–346. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Pal T, Permuth-Wey J and Sellers TA: A
review of the clinical relevance of mismatch-repair deficiency in
ovarian cancer. Cancer. 113:733–742. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Grady WM and Carethers JM: Genomic and
epigenetic instability in colorectal cancer pathogenesis.
Gastroenterology. 135:1079–1099. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Hudler P: Genetic aspects of gastric
cancer instability. Scientific World Journal. 2012:7619092012.
View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Perucho M: Cancer of the microsatellite
mutator phenotype. Biol Chem. 377:675–684. 1996.PubMed/NCBI
|
|
105
|
Mori Y, Yin J, Rashid A, Leggett BA, Young
J, Simms L, Kuehl PM, Langenberg P, Meltzer SJ and Stine OC:
Instabilotyping: Comprehensive identification of frameshift
mutations caused by coding region microsatellite instability.
Cancer Res. 61:6046–6049. 2001.PubMed/NCBI
|
|
106
|
Parsons R, Myeroff LL, Liu B, Wilison JK
V, Markowitz SD, Kinzler KW and Vogelstein B: Microsatellite
instability and mutations of the transforming growth factor β type
II receptor gene in colorectal cancer. Cancer Res. 55:5548–5550.
1995.PubMed/NCBI
|
|
107
|
Boland CR and Goel A: Microsatellite
instability in colorectal cancer. Gastroenterology.
138:2073–2087.e3. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Toyota M, Ahuja N, Ohe-Toyota M, Herman
JG, Baylin SB and Issa JP: CpG island methylator phenotype in
colorectal cancer. Proc Natl Acad Sci USA. 96:8681–8686. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Lao VV and Grady WM: Epigenetics and
colorectal cancer. Nat Rev Gastroenterol Hepatol. 8:686–700. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Jones PA and Laird PW: Cancer epigenetics
comes of age. Nat Genet. 21:163–167. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Laird PW: Cancer epigenetics. Hum Mol
Genet. 14:R65–R76. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Jass JR: Serrated adenoma of the
colorectum and the DNA-methylator phenotype. Nat Clin Pract Oncol.
2:398–405. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Samowitz WS, Albertsen H, Herrick J, Levin
TR, Sweeney C, Murtaugh MA, Wolff RK and Slattery ML: Evaluation of
a large, population-based sample supports a CpG island methylator
phenotype in colon cancer. Gastroenterology. 129:837–845. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Ogino S, Cantor M, Kawasaki T, Brahmandam
M, Kirkner GJ, Weisenberger DJ, Campan M, Laird PW, Loda M and
Fuchs CS: CpG island methylator phenotype (CIMP) of colorectal
cancer is best characterised by quantitative DNA methylation
analysis and prospective cohort studies. Gut. 55:1000–1006. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Weisenberger DJ, Siegmund KD, Campan M,
Young J, Long TI, Faasse MA, Kang GH, Widschwendter M, Weener D,
Buchanan D, et al: CpG island methylator phenotype underlies
sporadic microsatellite instability and is tightly associated with
BRAF mutation in colorectal cancer. Nat Genet. 38:787–793. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Worthley DL and Leggett BA: Colorectal
cancer: Molecular features and clinical opportunities. Clin Biochem
Rev. 31:31–38. 2010.PubMed/NCBI
|
|
117
|
Ogino S, Kawasaki T, Kirkner GJ, Ohnishi M
and Fuchs CS: 18q loss of heterozygosity in microsatellite stable
colorectal cancer is correlated with CpG island methylator
phenotype-negative (CIMP-0) and inversely with CIMP-low and
CIMP-high. BMC Cancer. 7:722007. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Ogino S, Kawasaki T, Kirkner GJ, Kraft P,
Loda M and Fuchs CS: Evaluation of markers for CpG island
methylator phenotype (CIMP) in colorectal cancer by a large
population-based sample. J Mol Diagn. 9:305–314. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Toyota M, Ohe-Toyota M, Ahuja N and Issa
JP: Distinct genetic profiles in colorectal tumors with or without
the CpG island methylator phenotype. Proc Natl Acad Sci USA.
97:710–715. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Kambara T, Simms LA, Whitehall VLJ, Spring
KJ, Wynter CVA, Walsh MD, Barker MA, Arnold S, McGivern A,
Matsubara N, et al: BRAF mutation is associated with DNA
methylation in serrated polyps and cancers of the colorectum. Gut.
53:1137–1144. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Hawkins N, Norrie M, Cheong K, Mokany E,
Ku SL, Meagher A, OConnor T and Ward R: CpG island methylation in
sporadic colorectal cancers and its relationship to microsatellite
instability. Gastroenterology. 122:1376–1387. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Shen L, Toyota M, Kondo Y, Lin E, Zhang L,
Guo Y, Hernandez NS, Chen X, Ahmed S, Konishi K, et al: Integrated
genetic and epigenetic analysis identifies three different
subclasses of colon cancer. Proc Natl Acad Sci USA.
104:18654–18659. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Munro AJ, Lain S and Lane DP: P53
abnormalities and outcomes in colorectal cancer: A systematic
review. Br J Cancer. 92:434–444. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Van Cutsem E, Peeters M, Siena S, Humblet
Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J,
Richardson G, et al: Open-label phase III trial of panitumumab plus
best supportive care compared with best supportive care alone in
patients with chemotherapy-refractory metastatic colorectal cancer.
J Clin Oncol. 25:1658–1664. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Heinemann V, Stintzing S, Kirchner T,
Boeck S and Jung A: Clinical relevance of EGFR- and KRAS-status in
colorectal cancer patients treated with monoclonal antibodies
directed against the EGFR. Cancer Treat Rev. 35:262–271. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Boland CR: The molecular biology of
gastrointestinal cancer: Implications for diagnosis and therapy.
Gastrointest Endosc Clin N Am. 18:401–413. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Sinicrope FA, Foster NR, Thibodeau SN,
Marsoni S, Monges G, Labianca R, Kim GP, Yothers G, Allegra C,
Moore MJ, et al: DNA mismatch repair status and colon cancer
recurrence and survival in clinical trials of 5-fluorouracil-based
adjuvant therapy. J Natl Cancer Inst. 103:863–875. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Roth AD, Delorenzi M, Tejpar S, Yan P,
Klingbiel D, Fiocca R, d'Ario G, Cisar L, Labianca R, Cunningham D,
et al: Integrated analysis of molecular and clinical prognostic
factors in stage II/III colon cancer. J Natl Cancer Inst.
104:1635–1646. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Popat S, Hubner R and Houlston RS:
Systematic review of microsatellite instability and colorectal
cancer prognosis. J Clin Oncol. 23:609–618. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Al-Sohaily S, Biankin A, Leong R,
Kohonen-Corish M and Warusavitarne J: Molecular pathways in
colorectal cancer. J Gastroenterol Hepatol. 27:1423–1431. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Ribic CM, Sargent DJ, Moore MJ, Thibodeau
SN, French AJ, Goldberg RM, Hamilton SR, Laurent-Puig P, Gryfe R,
Shepherd LE, et al: Tumor microsatellite-instability status as a
predictor of benefit from fluorouracil-based adjuvant chemotherapy
for colon cancer. N Engl J Med. 349:247–257. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Sargent DJ, Marsoni S, Monges G, Thibodeau
SN, Labianca R, Hamilton SR, French AJ, Kabat B, Foster NR, Torri
V, et al: Defective mismatch repair as a predictive marker for lack
of efficacy of fluorouracil-based adjuvant therapy in colon cancer.
J Clin Oncol. 28:3219–3226. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Yang L, Sun Y, Huang XE, Yu DS, Zhou JN,
Zhou X, Li DZ and Guan X: Carcinoma microsatellite instability
status as a predictor of benefit from fluorouracil-based adjuvant
chemotherapy for stage II rectal cancer. Asian Pacific J Cancer
Prev. 16:1545–1551. 2015. View Article : Google Scholar
|
|
134
|
Tejpar S, Saridaki Z, Delorenzi M, Bosman
F and Roth AD: Microsatellite instability, prognosis and drug
sensitivity of stage II and III colorectal cancer: More complexity
to the puzzle. J Natl Cancer Inst. 103:841–844. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Des Guetz G, Schischmanoff O, Nicolas P,
Perret GY, Morere JF and Uzzan B: Does microsatellite instability
predict the efficacy of adjuvant chemotherapy in colorectal cancer?
A systematic review with meta-analysis. Eur J Cancer. 45:1890–1896.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
De Sousa E, Melo F, Wang X, Jansen M,
Fessler E, Trinh A, de Rooij LP, de Jong JH, de Boer OJ, van
Leersum R, Bijlsma MF, et al: Poor-prognosis colon cancer is
defined by a molecularly distinct subtype and develops from
serrated precursor lesions. Nat Med. 19:614–618. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Sadanandam A, Lyssiotis CA, Homicsko K,
Collisson EA, Gibb WJ, Wullschleger S, Ostos LC, Lannon WA,
Grotzinger C, Del Rio M, et al: A colorectal cancer classification
system that associates cellular phenotype and responses to therapy.
Nat Med. 19:619–625. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
De Rosa M, Pace U, Rega D, Costabile V,
Duraturo F, Izzo P and Delrio P: Genetics, diagnosis and management
of colorectal cancer (Review). Oncol Rep. 34:1087–1096. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Su S, Hu B, Shao J, Shen B, Du J, Du Y,
Zhou J, Yu L, Zhang L, Chen F, et al: CRISPR-Cas9 mediated
efficient PD-1 disruption on human primary T cells from cancer
patients. Sci Rep. 6:200702016. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Liao Y, Chen L, Feng Y, Shen J, Gao Y,
Cote G, Choy E, Harmon D, Mankin H, Hornicek F and Duan Z:
Targeting programmed cell death ligand 1 by CRISPR/Cas9 in
osteosarcoma cells. Oncotarget. 8:30276–30287. 2017. View Article : Google Scholar : PubMed/NCBI
|
